INPP5D and Alzheimer disease: However, since studies such as those by Sala Figerio et al. [75] have emphasized that SHIP1 diminution can also be very important in AD progression, it may be reasonably inferred that SHIP1 agonism should also be considered as a possible therapeutic option for AD.